bf-1

BF-1 is a novel selective 5-HT2 receptor antagonist that acts by blocking neurogenic dural plasma protein extravasation induced by mCPP or BW723C86.BF-1 is used in the study of migraine.

BF-168 is a candidate probe for PET and specifically recognizes both neuritic and diffuse plaques (Ki: 6.4 nM for Aβ1-42).

BF-170 is a selective tau fiber-binding agent with an EC50 of 221 nM. It demonstrates excellent blood-brain barrier penetration, reaching a concentration of 9.1% ID g in brain tissue 2 minutes after intravenous injection in mice (with a clearance rate of 0.25% ID g at 30 minutes). BF-170 can serve as a probe for imaging tau protein pathology in Alzheimer's disease (AD). It plays a significant role in early-stage Alzheimer's disease studies and holds promise for imaging research in tau-related neurodegenerative diseases.

BF-158 is used for imaging tau protein.

BF1 is an inhibitor of HAT (histone acetyltransferase) active both in vitro and in vivo.

HNC-1664 is an orally active inhibitor of RNA-dependent RNA polymerase (RdRP). It exhibits broad-spectrum antiviral activity against coronaviruses, including SARS-CoV-2 wild type and its variants (XBB.1.18, HK.3.1, BF.7.14, BA.1, HCoV-229E, HCoV-OC43), as well as arenaviruses. HNC-1664 also demonstrates anti-infective efficacy in a mouse model infected with the SARS-CoV-2 Delta variant.

MOA-stilbene, also known as 3-Methoxy-2-(2-styrylphenyl)propenic acid methyl ester, is a fluorescence inhibitor. MOA-stilbene is a new tool for investigation of the reactions of the chloroplast cytochrome bf complex. MOA-stilbene is known to be a specific inhibitor of the Qo site of mammalian cytochrome bc 1 complex.